Astellas Pharma Inc. ALPMF
15.96 USD -0.90 (-5.34%)
At closeNov 11, 2026, 4:00 PM EST
16.00 Day range 16.00
11.40 52-week range 18.03
- YTD
- +21.18%
- 1 year
- +41.11%
- Market cap
- 28.62B
- EPS (ttm)
- 1.36
- P/E ratio
- 11.74
- YTD return
- +21.18%
- 1-year return
- +41.11%
- Volume
- 200
- Avg volume
- 5.96K
- Open
- 16.00
- Previous close
- 16.86
- Day's range
- 16.00 – 16.00
- 52-week range
- 11.40 – 18.03
- Earnings date
- Nov 4, 2026
5D +0.86 (+5.37%)
Next earnings
Nov 4, 2026
Expected Nov 4, 2026. Consensus EPS estimate 0.3937.
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 4, 2026 | Sep 30, 2026 | 0.3937 | — | — | — |
| Aug 5, 2026 | Jun 30, 2026 | 0.3327 | 0.4867 | +0.15 | +46.29% |
| Apr 27, 2026 | Mar 31, 2026 | 0.1926 | 0.153 | -0.04 | -20.56% |
| Feb 4, 2026 | Dec 31, 2025 | 0.2931 | 0.3576 | +0.06 | +22.01% |
| Oct 30, 2025 | Sep 30, 2025 | 0.2015 | 0.2989 | +0.10 | +48.34% |
| Jul 30, 2025 | Jun 30, 2025 | 0.1379 | 0.2652 | +0.13 | +92.31% |
News
Merck Advances European Regulatory Approval For Keytruda Combination In Bladder Cancer 
Impax International Sustainable Economy Fund Q2 2026 Contributors And Detractors 
Astellas Pharma Inc. (ALPMY) Q4 2026 Earnings Call Transcript 
Astellas Pharma Inc. (ALPMY) Discusses R&D Strategy and Focus Areas in Innovative Healthcare Transcript 
Vir Biotechnology: Up On Prostate Data And Astellas Deal - I'm (Long-Term) Bullish 
These Analysts Boost Their Forecasts On Vir Biotechnology 
What's Going On With Kyntra Bio Stock Tuesday? 
Vir Biotechnology Stock Hits 52-Week High Tuesday - Here's Why 
Astellas and Vir Biotechnology Announce Global Strategic Collaboration to Advance PSMA-targeting PRO-XTEN® Dual-masked T-Cell Engager VIR-5500 for the Treatment of Prostate Cancer 
India's Lupin clears patent hurdle with Astellas Pharma, keeps Mirabegron sales in US
Your note
Sign in to keep a note on ALPMF — it syncs with the Stock Master app.